Founded in 2015, Laboratoire XO is an asset light specialty pharmaceutical company marketing established, mature prescription and OTC products across various therapeutic areas, including cardiovascular (CVS), anesthesia, central nervous system (CNS), rheumatology and oral case, among others. The business developed through both organic growth (via international expansion) and inorganic growth.
LXO benefits from a management team who are experienced in both M&A and the lifecycle management skills to help grow acquired products.
In addition to M&A, we have identified several organic growth initiatives which form the basis of our strategy. These include strengthening lifecycle management capabilities, implementing a digital go-to-market strategy, diversifying organic growth via in-licensing partnerships, scaling the organisation, reboosting OTC and optimising operations.